Faron Pharmaceuticals Oy (LSE:FARN) Beta: 0.2973 (As of Jun. 29, 2026)


LSE:FARN Faron Pharmaceuticals Oy LSE:FARN
22 GF Score
Price £0.41
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Beta?

Faron Pharmaceuticals Oy LSE:FARN -0.24% 22 Beta is 0.2973 as of Jun. 29, 2026. GuruFocus rates LSE:FARN with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-29), Faron Pharmaceuticals Oy's Beta is 0.2973.


Faron Pharmaceuticals Oy  (LSE:FARN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Faron Pharmaceuticals Oy Beta Related Terms


Faron Pharmaceuticals Oy Beta Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Beta Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.80 3.39 2.13

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.80 2.71 3.39 3.01 2.13

LSE:FARN vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Beta distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Beta falls into.


LSE:FARN
22GF Score
Faron Pharmaceuticals Oy LSE:FARN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2973 mean?
Faron Pharmaceuticals Oy (LSE:FARN) has a Beta of 0.2973 as of Jun. 29, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's Beta too high?
Faron Pharmaceuticals Oy's current Beta is 0.2973. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Beta compare to VRTX and REGN?
Faron Pharmaceuticals Oy's Beta of 0.2973 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Beta is 0.2973. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (LSE:FARN) has a current Beta of 0.2973. The current Beta is 0.2973. Faron Pharmaceuticals Oy's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (LSE:FARN), the current Beta is 0.2973 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARON:Finland4FR:Germany
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
22GF Score

Get the complete analysis for LSE:FARN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.41
Price